Showing 1 - 10 of 33
Unlock and Rock: Empowering Haemophilia Families
Published on 24/10/2025
» In a continued effort to enhance healthcare awareness and support for rare diseases, Chonburi Hospital, in collaboration with Novo Nordisk Pharma (Thailand) Ltd. (“Novo Nordisk”), hosted the “Unlock and Rock Haemophilia” event. The initiative aimed to raise awareness and strengthen understanding of haemophilia among children, patients, and their families, while engaging the haemophilia community in Eastern Thailand through the Thai Hemophilia Patient Club.
Challenges to clinical trial growth in Thailand
Business, Published on 15/10/2025
» Thailand has potential to become an increasingly attractive location for pharmaceutical companies to conduct clinical trials. The total number of clinical trials conducted in 2024 was 527, an increase of 1.9% from 2023, BMI research has found.
Novo Nordisk Completes Landmark Diabetes Affordability Project
Published on 31/07/2025
» Bangkok, - Novo Nordisk Pharma (Thailand) Ltd. (Novo Nordisk) today announced the successful completion of the Affordability Project in Thailand as part of its ongoing commitment to drive change in diabetes in the country. This transformative initiative was launched in collaboration with the Department of Medical Services, Ministry of Public Health. Over the past three years, the project has actively addressed the rising diabetic problems in Thailand through a public-private partnership with the Thai state-owned Rajavithi Hospital, Institute of Medical Research & Technology Assessment and Bureau of Medical System Supervision as the project’s main implementor.
Novo Nordisk Brings Cities for Better Health to Bangkok
Published on 11/07/2025
» Bangkok, July 11, 2025 — Following a visit to Copenhagen, Denmark, to collaborate on enhancing urban health, the Bangkok Metropolitan Administration (BMA) and Novo Nordisk will launch the Cities for Better Health (CBH) programme in Bangkok in 2025.
Novo Nordisk Thailand and HSRI MoU Enhances Clinical Research Standards
Published on 02/06/2025
» The rapid advancement of medical technology is playing a vital role in enhancing the health system and quality of life for individuals in Thailand. Clinical research is essential in facilitating the development of new medications, devices, and treatment methodologies for complex and rare diseases. Reports indicate that nations such as China, the United States, various African countries, and others in Asia are significantly increasing their investments in medical research and development (R&D). Thailand has been classified as an ‘opportunity tier’, possessing a large number of patients ready for treatment. This presents researchers with numerous opportunities for trial volunteers, making Thailand more competitive compared to Europe and the US, where research costs tend to be higher.
Thammasat, Novo Nordisk Unite for Holistic Diabetes, Obesity Care
Published on 28/05/2025
» Thammasat University Hospital, in collaboration with Novo Nordisk Pharma (Thailand) Ltd. (“Novo Nordisk”), announced a collaboration titled “Partnership Project for the Transition into the Fourth Decade of Thammasat University Hospital: Beat Obesity Beat Diabetes” at the Thammasat University Hospital. The public-private partnership aims to enhance holistic patient care and expand equitable access for all.
Novo Nordisk Leads Obesity Fight in Thailand
Published on 20/05/2025
» Bangkok, May 2025 – Novo Nordisk, the global pharmaceutical leader headquartered in Denmark, has launched a major initiative to combat Thailand’s growing obesity crisis, where more than 40% of the population is now classified as overweight or obese.
Novo Nordisk Launches Campaign to Tackle Obesity
Published on 20/05/2025
» Novo Nordisk Pharma (Thailand) Ltd. is advancing its commitment to sustainable weight management among Thais through the launch of the “From My Weight to My Heart” campaign, aimed at reducing the risk of cardiovascular diseases and non-communicable diseases (NCDs)—key global health challenges. The campaign debuted with an inspirational panel featuring leading public figures.
Novo Nordisk, Nanyang Launch Shoes for Haemophilia Awareness
Published on 08/05/2025
» Bangkok, Thailand – 6 May 2025 – Novo Nordisk Pharma (Thailand) Ltd. (Novo Nordisk), a global healthcare company committed to driving change in chronic diseases, has announced the delivery of unique shoes, produced in collaboration with renowned Thai shoe manufacturer Nanyang, to the Thai Haemophilia Patient Club. The collaboration aims to enhance awareness of haemophilia in Thailand, underscoring the message of equitable access to healthcare.
Novo Nordisk Leads Danish-Thai Forum on Obesity Solutions
Published on 08/05/2025
» The Royal Danish Embassy in Thailand, in collaboration with Novo Nordisk Pharma (Thailand) Ltd. (“Novo Nordisk”), organised the first Danish-Thai Obesity Policy Forum, bringing together top policymakers, healthcare professionals and industry representatives to discuss challenges arising from the growing prevalence of obesity and its socio-economic impacts in Thailand. The forum, titled “Obesity – A National Threat to Health and Wealth, Act Now for Our Future Generations”, featured remarks from decision-makers and a panel discussion.